Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	93156
Country	South Korea

Received	2024-02-21 05:58
Peer-Review Started	2024-02-21 05:58
To Make the First Decision
Return for Revision	2024-04-13 19:44
Revised	2024-05-02 00:59
Second Decision	2024-06-11 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-11 08:06
Articles in Press	2024-06-11 08:06
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-06-24 12:17
Typeset the Manuscript	2024-07-17 05:45
Publish the Manuscript Online	2024-08-08 04:58

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Observational Study
Article Title	Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1
Manuscript Source	Unsolicited Manuscript
All Author List	Shin Woo Kang, Sung Hee Lim, Min-Ji Kim, Jeeyun Lee, Young Suk Park, Ho Yeong Lim, Won Ki Kang and Seung Tae Kim
ORCID	Author(s) ORCID Number Seung Tae Kim http://orcid.org/0000-0001-7335-1846
Funding Agency and Grant Number
Corresponding Author	Seung Tae Kim, MD, PhD, Professor, Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul 06351, South Korea. seungtae1.kim@samsung.com
Key Words	Bevacizumab; Colorectal cancer; Programmed cell death ligand 1 expression; First-line chemotherapy; Metastatic colorectal cancer
Core Tip	Efficacy of first line chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in metastatic colorectal cancer was not significantly different according to the status of tumor tissue programmed cell death ligand 1 (PD-L1) CPS status. Further research regarding dual inhibition of the vascular endothelial growth factor and PD-L1/programmed death 1 axes in various tumor types including colorectal cancer is required.
Publish Date	2024-08-08 04:58
Citation	<p>Kang SW, Lim SH, Kim MJ, Lee J, Park YS, Lim HY, Kang WK, Kim ST. Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1. <i>World J Gastrointest Oncol</i> 2024; 16(8): 3521-3528</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i8/3521.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i8.3521

Full Article (PDF)	WJGO-16-3521-with-cover.pdf
STROBE Statement	93156-STROBE-statement.pdf
Manuscript File	93156_Auto_Edited-YJP-Language editing-Webster J.docx
Answering Reviewers	93156-answering-reviewers.pdf
Audio Core Tip	93156-audio.m4a
Biostatistics Review Certificate	93156-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	93156-conflict-of-interest-statement.pdf
Copyright License Agreement	93156-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	93156-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	93156-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	93156-non-native-speakers.pdf
Supplementary Material	93156-supplementary-material.pdf
Peer-review Report	93156-peer-reviews.pdf
Scientific Misconduct Check	93156-scientific-misconduct-check.png
Scientific Editor Work List	93156-scientific-editor-work-list.pdf
CrossCheck Report	93156-crosscheck-report.pdf